目的:研究肝细胞癌(hepatocelluar carcinoma,HCC)中高迁移率族蛋白A1(high mobility group protein A1,HMGA1)的表达情况,探讨HMGA1基因在HCC中的表达与肝内转移以及临床病理参数之间的关系。方法:采用实时定量荧光聚合酶链反应(real-t...目的:研究肝细胞癌(hepatocelluar carcinoma,HCC)中高迁移率族蛋白A1(high mobility group protein A1,HMGA1)的表达情况,探讨HMGA1基因在HCC中的表达与肝内转移以及临床病理参数之间的关系。方法:采用实时定量荧光聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction,QRT-PCR)检测52例肝细胞癌组织和配对的癌旁组织、10例正常肝脏组织中HMGA1mRNA的表达,用免疫组化法(immunohistochemistry,IHC)检测HMGA1蛋白在肝细胞癌中的表达,评价HMGA1的表达与HCC临床病理学因素的相关性。结果:肝癌组织中HMGA1mRNA的表达较正常肝脏中升高6.82倍,其中有、无肝内转移组较正常肝组织分别升高13.36倍和4.63倍(P<0.05)。HMGA1mRNA的表达与TNM分期、Edmonson分级、肝内转移有关(P<0.05)。肝细胞癌中有肝内转移组较无肝内转移组HMGA1蛋白表达明显增强。结论:HMGA1基因在肝细胞癌中的表达较正常肝脏组织中明显升高,并与肿瘤的肝内转移相关,有望成为肝细胞癌诊断和治疗的新靶点。展开更多
Presented here is the clinical course of a 63-yearold patient with a central, large and unresectable hepatocellular carcinoma(HCC) with liver metastases and tumor invasion of the portal and hepatic veins. After the tu...Presented here is the clinical course of a 63-yearold patient with a central, large and unresectable hepatocellular carcinoma(HCC) with liver metastases and tumor invasion of the portal and hepatic veins. After the tumor had been diagnosed, the patient was immediately treated with proton beam therapy(PBT), at a total dose of 60 Gy(relative biological effectiveness) in 20 fractions administered within 4 wk. To manage the respiratory movements, at the Rinecker Proton Therapy Center, apneic oxygenation was given daily, under general anesthesia. The patient tolerated both the PBT and general anesthesia very well, and did now show any signs of acute or late toxicity. The treatment was followed by constant reductions in the tumor marker alpha-fetoprotein and the cholestatic parameters gamma-glutamyltransferase and alkaline phosphatase. The patient commenced an adjuvant treatment with sorafenib, given at 6-wk intervals, after the PBT. Follow-up with regular magnetic resonance imaging has continued for 40 mo so far, demonstrating remarkable shrinkage of the HCC(maximal diameter dropping from approximately 13 cm to 2 cm). To date, the patient remains free of tumor recurrence. PBT served as a safe and effective treatment method for an unresectable HCC with vascular invasion.展开更多
基金Supported by Rinecker Proton Therapy Center(RPTC),Munich,Germany
文摘Presented here is the clinical course of a 63-yearold patient with a central, large and unresectable hepatocellular carcinoma(HCC) with liver metastases and tumor invasion of the portal and hepatic veins. After the tumor had been diagnosed, the patient was immediately treated with proton beam therapy(PBT), at a total dose of 60 Gy(relative biological effectiveness) in 20 fractions administered within 4 wk. To manage the respiratory movements, at the Rinecker Proton Therapy Center, apneic oxygenation was given daily, under general anesthesia. The patient tolerated both the PBT and general anesthesia very well, and did now show any signs of acute or late toxicity. The treatment was followed by constant reductions in the tumor marker alpha-fetoprotein and the cholestatic parameters gamma-glutamyltransferase and alkaline phosphatase. The patient commenced an adjuvant treatment with sorafenib, given at 6-wk intervals, after the PBT. Follow-up with regular magnetic resonance imaging has continued for 40 mo so far, demonstrating remarkable shrinkage of the HCC(maximal diameter dropping from approximately 13 cm to 2 cm). To date, the patient remains free of tumor recurrence. PBT served as a safe and effective treatment method for an unresectable HCC with vascular invasion.
